Key result
Higher circulating MCP-1 levels were associated with increased cardiovascular mortality in individuals free of overt cardiovascular disease.
Why the study?
Associations of circulating monocyte-chemoattractant protein-1 (MCP-1) levels with risk of coronary heart disease and cardiovascular death in the general population remained largely unexplored.
Are higher circulating MCP-1 levels associated with increased risk of incident coronary heart disease and cardiovascular mortality in individuals free of overt cardiovascular disease?
Meta-Analysis (n=21,401)
Yes
Are higher circulating MCP-1 levels associated with increased risk of incident coronary heart disease and cardiovascular mortality in individuals free of overt cardiovascular disease?
Answers are grounded in this paper and cite their sources.
Higher circulating MCP-1 levels are associated with increased long-term cardiovascular mortality in individuals without baseline cardiovascular disease, supporting its role in atherosclerosis.
Importance: Human genetics and studies in experimental models support a key role of monocyte-chemoattractant protein-1 (MCP-1) in atherosclerosis. Yet, the associations of circulating MCP-1 levels with risk of coronary heart disease and cardiovascular death in the general population remain largely unexplored. Objective: To explore whether circulating levels of MCP-1 are associated with risk of incident coronary heart disease, myocardial infarction, and cardiovascular mortality in the general population. Data Sources and Selection: Population-based cohort studies, identified through a systematic review, that have examined associations of circulating MCP-1 levels with cardiovascular end points. Data Extraction and Synthesis: Using a prespecified harmonized analysis plan, study-specific summary data were obtained from Cox regression models after excluding individuals with overt cardiovascular disease at baseline. Derived hazard ratios (HRs) were synthesized using random-effects meta-analyses. Main Outcomes and Measures: Incident coronary heart disease (myocardial infarction, coronary revascularization, and unstable angina), nonfatal myocardial infarction, and cardiovascular death (from cardiac or cerebrovascular causes). Results: The meta-analysis included 7 cohort studies involving 21 401 individuals (mean [SD] age, 53.7 [10.2] years; 10 012 men [46.8%]). Mean (SD) follow-up was 15.3 (4.5) years (326 392 person-years at risk). In models adjusting for age, sex, and race/ethnicity, higher MCP-1 levels at baseline were associated with increased risk of coronary heart disease (HR per 1-SD increment in MCP-1 levels: 1.06 [95% CI, 1.01-1.11]; P = .01), nonfatal myocardial infarction (HR, 1.07 [95% CI, 1.01-1.13]; P = .02), and cardiovascular death (HR, 1.12 [95% CI, 1.05-1.20]; P < .001). In analyses comparing MCP-1 quartiles, these associations followed dose-response patterns. After additionally adjusting for vascular risk factors, the risk estimates were attenuated, but the associations of MCP-1 levels with cardiovascular death remained statistically significant, as did the association of MCP-1 levels in the upper quartile with coronary heart disease. There was no significant heterogeneity; the results did not change in sensitivity analyses excluding events occurring in the first 5 years after MCP-1 measurement, and the risk estimates were stable after additional adjustments for circulating levels of interleukin-6 and high-sensitivity C-reactive protein. Conclusions and Relevance: Higher circulating MCP-1 levels are associated with higher long-term cardiovascular mortality in community-dwelling individuals free of overt cardiovascular disease. These findings provide further support for a key role of MCP-1-signaling in cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Georgakis et al. (2020) conducted a meta-analysis in Free of overt cardiovascular disease (n=21,401). Circulating monocyte chemoattractant protein-1 (MCP-1) levels vs. Lower MCP-1 levels was evaluated on Cardiovascular death (HR 1.12, 95% CI 1.05-1.20, p=<.001). Higher circulating MCP-1 levels were associated with increased cardiovascular mortality in individuals free of overt cardiovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: